Clinical Stroke Research
Stroke research is a vital component for patients at Cedars-Sinai's Stroke Program. Director David Palestrant,MD, and the Stroke Program's staff are currently involved in National Institutes of Health (NIH)-funded clinical trials relating to stroke prevention, acute stroke therapy and neuroimaging in stroke.
Because of their active participation in these and other clinical stroke research trials, the Stroke Program team are able to develop effective treatment options for stroke patients.
Current Clinical Trials
The Stroke Program at Cedars-Sinai is currently partnering with the Cedars-Sinai Neurovascular Center on clinical trials, as well as working with The Field Administration of Stroke Therapy. The links for more information are listed below.
- PENUMBRA IMAGING COLLABORATIVE STUDY (PICS): A Multicenter Trial to Assess Outcomes of Patients Revascularized by the Penumbra System (IRB#: Pro00017143)
- SAMMPRIS: Preventing Recurrent Stroke in Patients with Intracranial Stenosis, Stenting and Aggressive Medical Management (IRB#: Pro00015781)
- SAPPHIRE: Less Invasive Carotid Stenting Procedures for Patients at High Risk for Surgery for Blockages of Carotid Artery (IRB#: Pro00015014)
- THE FIELD ADMINISTRATION OF STROKE THERAPY: Magnesium Phase 3 Clinical Trial (FAST-Mag)
- INSULIN RESISTANCE INTERVENTION AFTER STROKE TRIAL
Closed Clinical Trials
- Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)
- Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS)
- Insulin Resistance Intervention after Stroke Trial (IRIS) -- currently on hold
Clinical Trials National Directory
Awards and Outcomes
Stroke Achievement Award
Representatives of the American Heart Association recently presented Cedars-Sinai with its "Get with the Guidelines-Stroke Gold Performance Achievement Award." The award recognizes Cedars-Sinai's success in implementing a higher standard of stroke care.
To receive the award, honorees have to demonstrate 85 percent adherence to the "Get with the Guidelines-Stroke" key measures for 24 or more consecutive months. These measures include aggressive use of medications like tPA, anti-thrombotics, anticoagulation therapy, DVT prophylaxis, cholesterol-reducing drugs and smoking cessation.
To learn more about this award, please click here.
For an appointment, a second opinion or more information, please call 1-800-CEDARS-1 (1-800-233-2771) or e-mail us.
